214 related articles for article (PubMed ID: 18036444)
1. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.
Alici E; Konstantinidis KV; Sutlu T; Aints A; Gahrton G; Ljunggren HG; Dilber MS
Exp Hematol; 2007 Dec; 35(12):1839-46. PubMed ID: 18036444
[TBL] [Abstract][Full Text] [Related]
2. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cells inhibit the development of autoantibody production in (C57BL/6 x DBA/2) F1 hybrid mice injected with DBA/2 spleen cells.
Harada M; Lin T; Kurosawa S; Maeda T; Umesue M; Itoh O; Matsuzaki G; Nomoto K
Cell Immunol; 1995 Mar; 161(1):42-9. PubMed ID: 7867084
[TBL] [Abstract][Full Text] [Related]
4. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
6. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.
Katsanis E; Xu Z; Anderson PM; Dancisak BB; Bausero MA; Weisdorf DJ; Blazar BR; Ochoa AC
Bone Marrow Transplant; 1994 Oct; 14(4):563-72. PubMed ID: 7858530
[TBL] [Abstract][Full Text] [Related]
7. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
8. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and functional characteristics of in vivo-induced interleukin-12-activated killer cells.
Nishimura T; Watanabe K; Lee U; Yahata T; Kobayashi M; Herrmann SH; Habu S
Immunol Lett; 1995 Dec; 48(3):167-74. PubMed ID: 8867847
[TBL] [Abstract][Full Text] [Related]
10. Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma.
Katsanis E; Weisdorf DJ; Miller JS
Bone Marrow Transplant; 1998 Jul; 22(2):185-91. PubMed ID: 9707028
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2.
Basse PH; Goldfarb RH; Herberman RB; Hokland ME
In Vivo; 1994; 8(1):17-24. PubMed ID: 8054506
[TBL] [Abstract][Full Text] [Related]
12. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
Lin SJ; Kuo ML
Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
[TBL] [Abstract][Full Text] [Related]
13. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
14. Retention of adoptively transferred interleukin-2-activated natural killer cells in tumor tissue.
Ribeiro U; Basse PH; Rosenstein M; Safatle-Ribeiro AV; Alhallak S; Goldfarb RH; Posner MC
Anticancer Res; 1997; 17(2A):1115-23. PubMed ID: 9137458
[TBL] [Abstract][Full Text] [Related]
15. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
[TBL] [Abstract][Full Text] [Related]
16. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility-1 antigen-specific bone marrow rejection in vivo.
Murphy WJ; Kumar V; Bennett M
Eur J Immunol; 1990 Aug; 20(8):1729-34. PubMed ID: 2209686
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
19. Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis.
Johansson BR; Unger ML; Albertsson P; Casselbrant A; Nannmark U; Hokland M
Nat Immun; 1996-1997; 15(2-3):87-97. PubMed ID: 9162267
[TBL] [Abstract][Full Text] [Related]
20. Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression.
Ganesan PL; Alexander SI; Watson D; Logan GJ; Zhang GY; Alexander IE
Cancer Immunol Immunother; 2007 Dec; 56(12):1955-65. PubMed ID: 17549473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
